3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
pembrolizumab
311
Nivolumab
159
Carboplatin
158
Cisplatin
140
Cyclophosphamide
135
Paclitaxel
129
Magnetic Resonance Spectroscopy
99
Specimen Handling
96
Radiotherapy
93
Gemcitabine
88
Dexamethasone
86
Biopsy
81
Ipilimumab
81
Docetaxel
78
Doxorubicin
77
Rituximab
71
Etoposide
69
durvalumab
62
Lenalidomide
61
Radiation
61
atezolizumab
60
Prednisone
59
Pemetrexed
58
Taxes
58
Bevacizumab
55
fludarabine
54
olaparib
53
Vincristine
52
Cytarabine
51
Fluorouracil
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
amino-acid, glucose, and electrolyte solution
×
1 year
×
Clear all
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts